Eradication of small intestinal bacterial overgrowth in irritable bowel syndrome using herbal therapy: A case report

Wright,Ciara P.; Dooley,Melissa T.; Leeson,Heather

doi:10.3892/ijfn.2021.23

Eradication of small intestinal bacterial overgrowth in irritable bowel syndrome using herbal therapy: A case report

Authors:
- Ciara P. Wright
- Melissa T. Dooley
- Heather Leeson
View Affiliations

Affiliations: Glenville Nutrition, Dublin D06 T265, Ireland, GastroLife, Dublin 18 D18 E7P4, Ireland
Published online on: December 6, 2021 https://doi.org/10.3892/ijfn.2021.23
Article Number: 13
Copyright: © Wright et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Small intestinal bacterial overgrowth (SIBO) is a common pathology in irritable bowel syndrome (IBS). Symptoms include bloating, excessive belching, flatulence, epigastric and abdominal pain, nausea, early satiety, fatigue and altered bowel habits. Given the high incidence of IBS globally, SIBO needs to be investigated in IBS using hydrogen and methane breath testing. Adherence to the North American Consensus 2017 or the updated guidelines from the Association of Gastrointestinal Physiology (AGIP) committee of the British Society of Gastroenterology 2019 is necessary to ensure that testing and diagnosis are standardised. The treatment of SIBO with antibiotics, most commonly rifaximin, may restore gastrointestinal function and reduce the symptoms of IBS. A number of herbal and nutraceutical supplements are known to exert antimicrobial effects. There is increasing awareness amongst the public regarding these herbal and nutraceutical supplements, and there is an increased demand for their use. The present study describes the case of a patient with severe IBS symptoms, scoring in the extreme category on a quality of life questionnaire validated for IBS and functional digestive disorders. The patient tested positive for SIBO, which was then eradicated using a herbal formulation containing garlic, berberine, oregano, grapefruit seed extract and caprylic acid, while following a diet low in fermentable oligo‑, di‑, mono‑saccharides and polyols (FODMAP). The patient's quality of life assessment markedly improved following treatment and the remaining symptoms improved at the 3‑month follow‑up performed by verbal confirmation.

View Figures

View References

1	Canavan C, West J and Card T: The epidemiology of irritable bowel syndrome. Clin Epidemiol. 6:71–80. 2014.PubMed/NCBI View Article : Google Scholar
2	Drossman DA and Hasler WL: Rome IV-Functional GI disorders: Disorders of gut-brain interaction. Gastroenterology. 150:1257–1261. 2016.PubMed/NCBI View Article : Google Scholar
3	Camilleri M: Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. 367:1626–1635. 2012.PubMed/NCBI View Article : Google Scholar
4	Pimentel M, Chow EJ and Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 95:3503–3506. 2000.PubMed/NCBI View Article : Google Scholar
5	Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C and Pimentel M: The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: Relationship with irritable bowel syndrome. Dig Dis Sci. 57:1321–1329. 2012.PubMed/NCBI View Article : Google Scholar
6	Carrara M, Desideri S, Azzurro M, Bulighin GM, Di Piramo D, Lomonaco L and Adamo S: Small intestine bacterial overgrowth in patients with irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 12:197–202. 2008.PubMed/NCBI
7	Ghoshal UC, Shukla R and Ghoshal U: Small intestinal bacterial overgrowth and irritable bowel syndrome: A bridge between functional organic dichotomy. Gut Liver. 11:196–208. 2017.PubMed/NCBI View Article : Google Scholar
8	Pimentel M, Saad RJ, Long MD and Rao SSC: ACG clinical guideline: Small intestinal bacterial overgrowth. Am J Gastroenterol. 115:165–178. 2020.PubMed/NCBI View Article : Google Scholar
9	Corazza GR, Menozzi MG, Strocchi A, Rasciti L, Vaira D, Lecchini R, Avanzini P, Chezzi C and Gasbarrini G: The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology. 98:302–309. 1990.PubMed/NCBI View Article : Google Scholar
10	American Gastroenterological Association medical position statement: Guidelines for the evaluation and management of chronic diarrhea. Gastroenterology. 116:1461–1463. 1999.PubMed/NCBI View Article : Google Scholar
11	Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Masciana R, Forgione A, Gabrieli ML, Perotti G, et al: Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 49:1877–1887. 2009.PubMed/NCBI View Article : Google Scholar
12	Kapil S, Duseja A, Sharma BK, Singla B, Chakraborti A, Das A, Ray P, Dhiman RK and Chawla Y: Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 31:213–221. 2016.PubMed/NCBI View Article : Google Scholar
13	Dukowicz AC, Lacy BE and Levine GM: Small intestinal bacterial overgrowth: A comprehensive review. Gastroenterol Hepatol (NY). 3:112–122. 2007.PubMed/NCBI
14	Saad RJ and Chey WD: Breath testing for small intestinal bacterial overgrowth: Maximizing test accuracy. Clin Gastroenterol Hepatol. 12:1964–1972. 2014.PubMed/NCBI View Article : Google Scholar
15	Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Schmulson M, Valdovinos M, Zakko S and Pimentel M: Hydrogen and methane-based breath testing in gastrointestinal disorders: The north American consensus. Am J Gastroenterol. 112:775–784. 2017.PubMed/NCBI View Article : Google Scholar
16	The Association of Gastrointestinal Physiology (AGIP) Committee of the British Society of Gastroenterology (2019). Association of Gastrointestinal Physiologists (AGIP) Proposed Standardised Testing Protocol for Hydrogen/Methane Breath Testing (HMBT) to Assess Small Intestinal Bacterial Overgrowth (SIBO) and Carbohydrate Malabsorption. 2019 British Society of Gastroenterology, (24 June 2019).
17	The European Parliament and the Council of the European Union Regulation: Regulation (EU) 20-16/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). Official Journal of the European Union 2018. Available from: https://eur-lex.europa.eu/eli/reg/2016/679/oj. Accessed at November, 2021.
18	Chassany O, Marquis P, Scherrer B, Read NW, Finger T, Bergmann JF, Fraitag B, Geneve J and Caulin C: Validation of a specific quality of life questionnaire for functional digestive disorders. Gut. 44:527–533. 1999.PubMed/NCBI View Article : Google Scholar
19	Monash University: The Low FODMAP Diet. Online May 2, 2019. https://www.monashfodmap.com/. Accessed November 10, 2019.
20	Shayto RH, Abou Mrad R and Sharara AI: Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol. 22:6638–6651. 2016.PubMed/NCBI View Article : Google Scholar
21	Pimentel M: Review article: Potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 43 (Suppl 1):S37–S49. 2016.PubMed/NCBI View Article : Google Scholar
22	Meyrat P, Safroneeva E and Schoepfer AM: Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther. 36:1084–1093. 2012.PubMed/NCBI View Article : Google Scholar
23	Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S and Elhajj I: A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 101:326–333. 2006.PubMed/NCBI View Article : Google Scholar
24	Pimentel M, Park S, Mirocha J, Kane SV and Kong Y: The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: A randomized trial. Ann Intern Med. 145:557–563. 2006.PubMed/NCBI View Article : Google Scholar
25	Lai PK and Roy J: Antimicrobial and chemopreventive properties of herbs and spices. Curr Med Chem. 11:1451–1460. 2004.PubMed/NCBI View Article : Google Scholar
26	Chedid V, Dhalla S, Clarke JO, Roland BC, Dunbar KB, Koh J, Justino E, Tomakin E and Mullin GE: Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Glob Adv Health Med. 3:16–24. 2014.PubMed/NCBI View Article : Google Scholar
27	Staudacher HM, Ralph FSE, Irving PM, Whelan K and Lomer MCE: Nutrient intake, diet quality, and diet diversity in irritable bowel syndrome and the impact of the low FODMAP Diet. J Acad Nutr Diet. 120:535–547. 2020.PubMed/NCBI View Article : Google Scholar
28	McIntosh K, Reed DE, Schneider T, Dang F, Keshteli AH, De Palma G, Madsen K, Bercik P and Vanner S: FODMAPs alter symptoms and the metabolome of patients with IBS: A randomised controlled trial. Gut. 66:1241–1251. 2017.PubMed/NCBI View Article : Google Scholar
29	Ong DK, Mitchell SB, Barrett JS, Shepherd SJ, Irving PM, Biesiekierski JR, Smith S, Gibson PR and Muir JG: Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol. 25:1366–1373. 2010.PubMed/NCBI View Article : Google Scholar
30	Hustoft TN, Hausken T, Ystad SO, Valeur J, Brokstad K, Hatlebakk JG and Lied GA: Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterol Motil: Oct 16, 2016 (Epub ahead of print). doi: 10.1111/nmo.12969.